- Home
- OMER vs CATX Comparison
OMER vs CATX Comparison
Compare OMER & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- CATX
- Stock Information
- Founded
- OMER 1994
- CATX 1983
- Country
- OMER United States
- CATX United States
- Employees
- OMER N/A
- CATX N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- OMER Health Care
- CATX Health Care
- Exchange
- OMER Nasdaq
- CATX Nasdaq
- Market Cap
- OMER 667.0M
- CATX 782.7M
- IPO Year
- OMER 2009
- CATX N/A
- Fundamental
- Price
- OMER $7.88
- CATX $3.07
- Analyst Decision
- OMER Buy
- CATX Strong Buy
- Analyst Count
- OMER 3
- CATX 9
- Target Price
- OMER $9.00
- CATX $17.25
- AVG Volume (30 Days)
- OMER 1.0M
- CATX 2.7M
- Earning Date
- OMER 11-13-2024
- CATX 11-12-2024
- Dividend Yield
- OMER N/A
- CATX N/A
- EPS Growth
- OMER N/A
- CATX N/A
- EPS
- OMER N/A
- CATX N/A
- Revenue
- OMER N/A
- CATX $1,557,000.00
- Revenue This Year
- OMER N/A
- CATX N/A
- Revenue Next Year
- OMER N/A
- CATX N/A
- P/E Ratio
- OMER N/A
- CATX N/A
- Revenue Growth
- OMER N/A
- CATX N/A
- 52 Week Low
- OMER $2.61
- CATX $2.50
- 52 Week High
- OMER $12.65
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- OMER 45.47
- CATX 20.31
- Support Level
- OMER $7.33
- CATX $3.27
- Resistance Level
- OMER $12.65
- CATX $3.60
- Average True Range (ATR)
- OMER 1.06
- CATX 0.33
- MACD
- OMER -0.63
- CATX 0.21
- Stochastic Oscillator
- OMER 10.34
- CATX 0.00
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.